Previous 10 | Next 10 |
Exelixis (NASDAQ: EXEL ): Q4 Non-GAAP EPS of $0.37 beats by $0.14 ; GAAP EPS of $1.15 beats by $0.92 . More news on: Exelixis, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 - - Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018 - - GAAP Diluted EPS of $1.15 for the...
– Phase 1 dose-escalation trial follows filing of IND in December 2018 – Exelixis, Inc. (Nasdaq: EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company...
ACGL , AIZ , AKAM , ATVI , AVLR , BFAM , BXMT , CNO , CRAY , CSOD , DEI , DENN , EXEL , GRPN , HUBS , IRTC , JCOM , LSCC , MPWR , OXY , QLYS , QUOT , REXR , RPAI , RRR , SHO , SPSC , TRIP , TWLO , UDR , UIS More news on: Arch Capital Group Ltd., Assurant, ...
̶ Presentation to be webcast on www.exelixis.com ̶ Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Guggenheim Healthcare Talks...
"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Exelixis, Inc. (NASDAQ:EXEL), Varian Medical Systems, Inc. (NYSE:VAR), DXC Tec...
Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF ) will team up with Roche (OTCQX: RHHBY ) to assess the combination of derazantinib,...
– Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m. PST – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2018 financial results will be released on Tuesday, February 12, 2019 after the markets close. At 5:00 p.m. EST...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...